/Jingjing Pharmaceutical: First Quarter Report of 2026

NEWS

Jingjing Pharmaceutical: First Quarter Report of 2026

Shenzhen Stock Exchange

2026/04/30

Jingjing Pharmaceutical Group Co., Ltd. 2026 First Quarter Report

Securities code: 002349 Securities abbreviation: Jingjing Pharmaceutical Announcement number: 2026-011

Jingjing Pharmaceutical Group Co., Ltd.

2026 First Quarter Report

The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions. Important content reminder:

The board of directors, directors and senior managers guarantee that the quarterly report is true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability.
The person in charge of the company, the person in charge of accounting work and the person in charge of the accounting department (accounting supervisor) declare that they guarantee the authenticity, accuracy and completeness of the financial information in the quarterly report.
Whether the first quarter financial accounting report has been audited

□Yes No

Jingjing Pharmaceutical Group Co., Ltd. 2026 First Quarter Report

1. Main financial data

(1) Main accounting data and financial indicators

Whether the company needs to retroactively adjust or restate previous years’ accounting data

□Yes No

Increases and decreases in this reporting period compared with the same period last year This reporting period compared with the same period last year

(%) Operating income (yuan) 379,763,838.00 363,535,559.83 4.46% Net profit attributable to shareholders of listed companies

65,872,510.07 62,219,690.39 5.87% profit (yuan)

Deductions attributable to shareholders of listed companies

Net profit from non-recurring gains and losses 63,823,539.15 60,349,142.87 5.76% (yuan)

Net cash flow from operating activities

36,455,008.57 61,601,252.72 -40.82% (yuan)

Basic earnings per share (yuan/share) 0.0809 0.0764 5.89% Diluted earnings per share (yuan/share) 0.0806 0.0764 5.50% Weighted average return on equity 2.36% 2.38% -0.02% Increase or decrease at the end of this reporting period compared with the end of the previous year The end of the reporting period The end of the previous year

(%) Total assets (yuan) 3,629,568,975.97 3,570,339,143.93 1.66% owned by shareholders of listed companies

2,824,437,763.51 2,752,711,273.75 2.61% interest (yuan)

(2) Non-recurring profit and loss items and amounts

Applicable □Not applicable

Unit: Yuan

Item Amount for this reporting period Description

Government subsidies included in current profits and losses (related to the company’s regular

Closely related to regular business operations and in compliance with national policies

215,340.00

stipulates, enjoys according to determined standards, and treats the company

Except for government subsidies that have a lasting impact on profits and losses)

Except for effective transactions related to the company’s normal business operations,

In addition to futures hedging business, non-financial enterprises hold financial

Changes in fair value of assets and financial liabilities 2,026,556.64

Profit and loss and disposal of financial assets and financial liabilities

profit and loss

Other non-operating income other than the above items and

425,874.17

expenditure

Less: Impact on income tax 371,154.08

Amount of impact on minority shareholders’ equity (after tax) 247,645.81

Total 2,048,970.92 --

Details of other profit and loss items that meet the definition of non-recurring profits and losses

□Applicable Not applicable

The company has no other specific circumstances of profit and loss items that meet the definition of non-recurring profits and losses.

Explanation on defining the non-recurring profit and loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-recurring Profit and Loss" as recurring profit and loss items

□Applicable Not applicable

Jingjing Pharmaceutical Group Co., Ltd. 2026 First Quarter Report

The company does not define the non-recurring profit and loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-Recurring Profit and Loss" as

The situation of items with recurring profits and losses.

(3) Changes in major accounting data and financial indicators and their reasons

Applicable □Not applicable

Balance sheet items March 31, 2026 End of 2025 Range of changes Reasons for changes

The main reason is the advance payment of raw materials purchased by the company and its subsidiaries during the reporting period 15,720,117.14 11,321,896.17 38.85%

Due to the increase in expected advance payments

The main reason is the short-term borrowing of the company's subsidiary Senxuan Medical Bank during the reporting period 3,154,780.00 1,679,219.23 87.87%

Due to increase in bank borrowings

The main reason is that the company and its subsidiaries bank acceptance notes payable during the reporting period - 1,920,000.00 -100.00%

Due to payment of bills of exchange due

The main reason is the taxes payable by the company's subsidiary Senxuan Pharmaceutical during the reporting period 28,541,963.48 20,962,808.81 36.16%

Increase in profits due to increase in corporate income tax payable

The main reason for non-compliance due within one year is the company's subsidiary Bozhou Baohetang during the reporting period 192,852.15 415,937.76 -53.63%

Current liabilities Result from adjustment of lease liabilities to other current liabilities

Income statement items January-March 2026 January-March 2025 Changes Reasons for changes

The main reason is the research and development expenses of the company and its subsidiaries during the reporting period 14,289,948.17 10,499,381.03 36.10%

The main reason for the increase and the increase in investment in some projects entering the pilot stage is the financial expenses of the company's subsidiary Senxuan Medical Hui during the reporting period -3,176,123.53 -4,749,911.40 33.13%

Caused by increased exchange losses

The main reason is that during the reporting period, the company's due financial management income increased investment income 711,451.63 472,032.72 50.72%

caused by

The change in fair value was mainly due to the increase in the company's unexpired financial management income during the reporting period 1,315,105.01 782,312.56 68.10%

Caused by benefit

The main reason is the credit impairment loss of the company's subsidiary Senxuan Pharmaceutical in the same period last year -1,846,252.06 -518,188.18 256.29%

Due to less losses from bad debts

The main reason is the income from asset disposal of the company's subsidiary Longxi Baohetang in the same period last year - 23905.98 -100.00%

Due to higher income from asset disposal

The main reason is the receipt of other non-daily operating income in the same period last year 433,483.91 760,227.89 -42.98%

Caused by excessive income

The main reason is other non-daily operating expenses incurred during the reporting period 7,609.74 1,154.91 558.90%

Due to high expenditure

Cash flow statement items January-March 2026 January-March 2025 Range of changes Reasons for changes

The main reason is the tax refund received by the company's subsidiary Senxuan Pharmaceutical during the reporting period 26943.37 655.75 4008.79%

Due to the increase in export tax rebates

The main reason is that in the same period last year, the company's subsidiary Senxuan Pharmaceutical received

6,140,050.19 9,715,305.91 -36.80% Bozhou Baohetang received cash related to other cash activities related to operating activities

Caused by more

The main reason for obtaining investment income is that the company’s financial management redemption income was relatively high during the reporting period 1,850,192.36 484,220.22 282.10%

Due to the cash received

Jingjing Pharmaceutical Group Co., Ltd. 2026 First Quarter Report

Dispose of fixed assets,

Intangible assets and other The main reason is that the company's subsidiary Longxi Baohetang in the same period last year

31000 -100.00%

Long-term asset recovery due to asset disposal

net cash

Distribute dividends and profits

The main reason is that the company repaid bank loan interest or paid interest in the same period last year 12750 56,750.00 -77.53%

due to paying more

of cash

Payments and other financing are mainly due to lease payments made by subsidiaries during the reporting period

188,818.00 413,209.98 -54.30%

Due to the decrease in cash amounts related to activities

Exchange rate changes against cash

The main reason is the change in the company's foreign currency deposit exchange rate and cash equivalents during the reporting period -1,597,926.44 -48,758.59 -3177.22%

caused by dynamic influence

influence

2. Shareholder information

(1) The total number of common shareholders, the number of preferred shareholders whose voting rights have been restored, and the shareholding status of the top ten shareholders

Unit: Share Total number of common shareholders at the end of the reporting period 80,720 Total number of preference shareholders whose voting rights were restored at the end of the reporting period (if any) 0 Shareholding status of the top 10 shareholders (excluding shares lent through refinancing)

Shareholding ratio Holding of sales restrictions Pledge, mark or freeze Name of shareholder Nature of shareholder Number of shares held

(%) Number of shares Share status Number Nantong Industrial Holdings

State-owned legal person 33.75% 279,994,660 0 Not applicable 0 Group Co., Ltd.

Jiangsu Nantong Port Gate

Economic Development Zone City

State-owned legal person 3.59% 29,826,020 0 Not applicable 0 Municipal construction and development company

Ltd.

Hong Kong Securities Clearing Company

Overseas legal person 1.54% 12,816,482 0 Not applicable 0 Limited company

China Construction Bank

Co., Ltd.

-China China Securities Co., Ltd.

Others 0.46% 3,790,100 0 Not applicable 0 Traditional Chinese medicine trading type

open index securities

investment fund

Zhou Yunzhong Domestic natural person 0.34% 2,792,966 593,500 Not applicable 0 Goldman Sachs International - Since

Overseas legal person 0.28% 2,322,812 0 Not applicable 0 With funds

GF Securities Co., Ltd.

Ltd. - West

Partially specialized

Others 0.27% 2,281,600 0 Not applicable 0 New quantitative stock selection mix

Combined Securities Investment

fund

CITIC Securities Co., Ltd.

Co., Ltd. - Peng

Huazhong Certificate of Traditional Chinese Medicine

Others 0.26% 2,175,600 0 Not applicable 0 Easy open-end index

Digital securities investment fund

gold

Jingjing Pharmaceutical Group Co., Ltd. 2026 First Quarter Report

Li Yuehui Domestic natural person 0.24% 1,967,100 0 Not applicable 0 Luo Yaqiong Domestic natural person 0.17% 1,446,300 0 Not applicable 0 Shareholdings of the top 10 shareholders without selling restrictions (excluding shares lent through refinancing and shares locked by executives)

Share type

Name of shareholder Number of shares without selling restrictions held

Type of shares Quantity Nantong Industrial Holding Group Co., Ltd. 279,994,660 RMB ordinary shares 279,994,660 Jiangsu Nantong Gangzha Economic Development Zone Urban Construction

29,826,020 RMB ordinary shares 29,826,020 Development Co., Ltd.

Hong Kong Securities Clearing Company Limited 12,816,482 RMB ordinary shares 12,816,482 China Construction Bank Corporation-Hui

Tianfu CSI Traditional Chinese Medicine Trading Open-End Index 3,790,100 RMB ordinary shares 3,790,100 Securities Investment Fund

Goldman Sachs International-Owned funds 2,322,812 RMB ordinary shares 2,322,812 GF Securities Co., Ltd.-Western Capital

Dezhong Special New Quantitative Stock Selection Hybrid Securities 2,281,600 RMB ordinary shares 2,281,600 investment funds

Zhou Yunzhong 2,199,466 RMB ordinary shares 2,199,466 CITIC Securities Co., Ltd.-Peng Huazhong

Traditional Chinese medicine trading open-end index securities investment 2,175,600 RMB ordinary shares 2,175,600 capital fund

Li Yuehui 1,967,100 RMB ordinary shares 1,967,100 Luo Yaqiong 1,446,300 RMB ordinary shares 1,446,300

It is unknown whether the other shareholders mentioned above are related to each other, nor is it clear whether there is a related relationship or concerted action among the above-mentioned shareholders.

To action people.

Li Yuehui holds 44,700 shares in his ordinary securities account, and explains the participation of the top 10 shareholders in margin trading and securities lending business through customer credit transactions (if any)

The account holds 1,922,400 shares, and the actual total holding is 1,967,100 shares;

The situation of shareholders holding more than 5% of the shares, the top 10 shareholders and the top 10 shareholders of unrestricted tradable shares participating in the refinancing business and lending shares

□Applicable Not applicable

The top 10 shareholders and the top 10 shareholders of unrestricted tradable shares have changed from the previous period due to refinancing lending/returning.

□Applicable Not applicable

(2) Total number of preferred shareholders of the company and shareholding status of the top 10 preferred shareholders

□Applicable Not applicable

3. Other important matters

□Applicable Not applicable

4. Quarterly Financial Statements

(1) Financial statements

Consolidated balance sheet

Prepared by: Jingjing Pharmaceutical Group Co., Ltd.

March 31, 2026

Unit: Yuan

Item Ending balance Beginning balance

Current assets:

Monetary funds 848,824,885.87 854,919,296.58

Settlement reserve fund

Jingjing Pharmaceutical Group Co., Ltd. 2026 First Quarter Report

Loan funds

Trading financial assets 395,666,610.33 434,740,246.05 Derivative financial assets

Notes receivable 38,115,870.08 32,411,268.05 Accounts receivable 359,989,000.62 321,922,090.82 Receivables financing 59,986,149.68 63,493,443.07 Prepayments 15,720,117.14 11,321,896.17 Premiums receivable

Reinsurance accounts receivable

Receivable reinsurance contract reserves

Other receivables 1,410,146.87 1,676,433.48 Including: interest receivable

Dividends receivable

Buy financial assets under resale agreements

Inventory 275,074,844.23 277,319,507.54

Among them: data resources

contract assets

Assets held for sale 28,048,550.29 28,048,550.29 Non-current assets due within one year

Other current assets 1,507,905.61 1,235,711.06 Total current assets 2,024,344,080.72 2,027,088,443.11 Non-current assets:

Grant loans and advances

debt investment

Other debt investments

long-term receivables

long term equity investment

Other equity instrument investments

Other non-current financial assets

Investment real estate 242,003,638.82 244,431,211.64 Fixed assets 525,173,183.96 535,900,915.56 Construction in progress 27,600,958.52 27,070,733.51 Productive biological assets

oil and gas assets

Right-of-use assets 2,574,930.06 2,183,600.43 Intangible assets 58,156,483.82 58,676,913.84

Among them: data resources

development expenditure

Among them: data resources

Goodwill 167,944,061.40 167,944,061.40 Long-term deferred expenses

Deferred income tax assets 7,049,376.77 6,979,229.93 Other non-current assets 574,722,261.90 500,064,034.51 Total non-current assets 1,605,224,895.25 1,543,250,700.82 Total assets 3,629,568,975.97 3,570,339,143.93 Current liabilities:

Short-term borrowings 3,154,780.00 1,679,219.23 Borrowings from the central bank

borrowing funds

Trading financial liabilities

Derivative financial liabilities

Notes payable 1,920,000.00 Accounts payable 139,875,881.31 153,483,714.37 Advance payments

Contract liabilities 13,165,815.90 12,216,819.25

Jingjing Pharmaceutical Group Co., Ltd. 2026 First Quarter Report

Financial assets sold and repurchased

Taking deposits and placing deposits with other banks

Agent for buying and selling securities

Agent underwriting securities funds

Employee benefits payable 50,221,665.27 64,335,276.42 Taxes payable 28,541,963.48 20,962,808.81 Other payables 112,469,456.41 122,894,069.51 Including: interest payable

Dividends payable

Handling fees and commissions payable

Reinsurance accounts payable

Liabilities held for sale

Non-current liabilities due within one year 192,852.15 415,937.76 Other current liabilities 17,550,096.75 16,879,570.09 Total current liabilities 365,172,511.27 394,787,415.44 Non-current liabilities:

insurance contract reserves

long term borrowing

bonds payable

Among them: preferred shares

perpetual bond

Lease liabilities 2,169,170.60 1,678,158.58 Long-term payables

Long-term employee benefits payable

Estimated liabilities 2,226,437.75 2,226,437.75 Deferred income 12,666,014.55 12,869,925.12 Deferred income tax liabilities 9,939,946.19 9,478,132.30 Other non-current liabilities 86,294.22 86,294.22 Total non-current liabilities 27,087,863.31 26,338,947.97 Total liabilities 392,260,374.58 421,126,363.41 Owners’ equity:

Share capital 829,674,908.00 829,674,908.00 Other equity instruments

Among them: preferred shares

perpetual bond

Capital reserve 828,433,768.46 823,466,004.69 Less: treasury shares 55,491,668.58 55,491,668.58 Other comprehensive income

Special reserves 6,789,932.71 5,903,716.79 Surplus reserves 143,177,433.56 143,177,433.56 General risk reserves

Undistributed profits 1,071,853,389.36 1,005,980,879.29 Total owners’ equity attributable to the parent company 2,824,437,763.51 2,752,711,273.75 Minority shareholders’ equity 412,870,837.88 396,501,506.77 Total owners’ equity 3,237,308,601.39 3,149,212,780.52 Total liabilities and owners’ equity 3,629,568,975.97 3,570,339,143.93 Legal representative: Yin Hongyu Person in charge of accounting work: Cheng Jian Person in charge of accounting department: Zhao Li

Consolidated income statement

Unit: Yuan

Item Amount for the current period Amount for the previous period

Total operating income 379,763,838.00 363,535,559.83 Including: operating income 379,763,838.00 363,535,559.83 Interest income

Premiums earned

Jingjing Pharmaceutical Group Co., Ltd. 2026 First Quarter Report

Fee and commission income

Total operating costs 283,381,216.65 279,284,981.39 Including: operating costs 169,416,002.59 175,127,814.59 Interest expenses

Handling fees and commission expenses

surrender deposit

Net compensation expenses

Net withdrawal of insurance liability reserves

policy dividend payout

Reinsurance cost

Taxes and surcharges 6,236,189.60 5,690,601.14 Sales expenses 65,068,369.08 62,075,019.03 Management expenses 31,546,830.74 30,642,077.00 Research and development expenses 14,289,948.17 10,499,381.03Financial expenses -3,176,123.53 -4,749,911.40Including: Interest expenses 116,594.96 228,985.49

Interest income 5,171,833.20 5,101,522.93 plus: other income 1,139,145.75 1,517,110.64 Investment income (losses are listed with "-") 711,451.63 472,032.72

Of which: for associates and joint ventures

investment income

Finance measured at amortized cost

Income from derecognition of assets

Exchange gains (losses are listed with "-")

Net exposure hedging income (losses are marked with a “-”

Fill in the column)

Gains from changes in fair value (losses are represented by “-”

No. 1,315,105.01 782,312.56 (please fill in the list)

Credit impairment losses (losses are filled in with "-"

-1,846,252.06 -518,188.18 columns)

Asset impairment losses (losses are filled in with "-"

-3,634,119.94 -3,776,994.23 columns)

Asset disposal income (losses are filled in with "-"

23,905.98 columns)

Operating profit (losses are listed with "-") 94,067,951.74 82,750,757.93 Plus: non-operating income 433,483.91 760,227.89 Less: non-operating expenses 7,609.74 1,154.91

4. Total profit (total loss is filled in with "-"

94,493,825.91 83,509,830.91 columns)

Less: Income tax expense 12,744,204.55 11,992,395.52

Net profit (net loss is listed with "-") 81,749,621.36 71,517,435.39

(1) Classification by business continuity

Net profit from continuing operations (net loss is represented by “-”

No. 81,749,621.36 71,517,435.39 (please fill in the list)

Net profit from discontinued operations (net loss is represented by “-”

(Fill in the number)

(2) Classification according to ownership ownership

Net profit attributable to owners of the parent company 65,872,510.07 62,219,690.39
Profit and loss of minority shareholders 15,877,111.29 9,297,745.00

Jingjing Pharmaceutical Group Co., Ltd. 2026 First Quarter Report

6. Net amount of other comprehensive income after tax

Taxes on other comprehensive income attributable to owners of the parent company

Net amount after

(1) Other comprehensive items that cannot be reclassified into profit or loss

income

Remeasure the changes in defined benefit plan
Other comprehensive items that cannot be transferred to profit or loss under the equity method

income

Changes in fair value of other equity instrument investments
Changes in the fair value of the company’s own credit risk

5.Others

(2) Other comprehensive income that will be reclassified into profit or loss

benefit

Other comprehensive income that can be transferred to profit or loss under the equity method

benefit

Changes in fair value of other debt investments
Financial assets are reclassified and included in other comprehensive income

amount of profit

Credit impairment provisions for other debt investments
Cash flow hedging reserve
Translation differences of foreign currency financial statements

7.Others

Other comprehensive income attributable to minority shareholders after tax

net amount

Total comprehensive income 81,749,621.36 71,517,435.39 Total comprehensive income attributable to owners of the parent company 65,872,510.07 62,219,690.39 Total comprehensive income attributable to minority shareholders 15,877,111.29 9,297,745.00

8. Earnings per share:

(1) Basic earnings per share 0.0809 0.0764

(2) Diluted earnings per share 0.0806 0.0764 If a business merger under the same control occurs in this period, the net profit realized by the merged party before the merger is: yuan, and the net profit realized by the merged party in the previous period is: yuan. Legal representative: Yin Hongyu Person in charge of accounting work: Cheng Jian Person in charge of accounting department: Zhao Li

Consolidated cash flow statement

Unit: Yuan

Item Amount for the current period Amount for the previous period

1. Cash flow generated from operating activities:

Cash received from sales of goods and provision of services 340,014,082.74 356,259,418.75 Net increase in customer deposits and interbank deposits

Net increase in borrowing from the central bank

Net increase in borrowing funds from other financial institutions

Cash received from premiums from the original insurance contract

Net cash received from reinsurance business

Net increase in policyholders’ savings and investment funds

Cash collected from interest, fees and commissions

Net increase in borrowing funds

Net increase in repurchase business funds

Net cash received from buying and selling securities on behalf of agents

Tax returns received 26,943.37 655.75 Other cash received related to operating activities 6,140,050.19 9,715,305.91 Subtotal of cash inflows from operating activities 346,181,076.30 365,975,380.41 Cash paid for purchasing goods and receiving services 120,634,463.88 117,998,241.56

Jingjing Pharmaceutical Group Co., Ltd. 2026 First Quarter Report

Net increase in loans and advances to customers

Net increase in deposits with central banks and inter-banks

Cash used to pay compensation from the original insurance contract

Net increase in lending funds

Cash payments for interest, fees and commissions

Cash payment for policy dividends

Cash paid to and for employees 103,755,059.90 98,809,298.56 Various taxes and fees paid 37,869,939.62 39,741,180.37

Other cash payments related to operating activities 47,466,604.33 47,825,407.20 Subtotal cash outflow from operating activities 309,726,067.73 304,374,127.69 Net cash flow generated from operating activities 36,455,008.57 61,601,252.72

2. Cash flow generated from investing activities:

Cash received from recovery of investment 328,250,000.00 275,000,000.00 Cash received from investment income 1,850,192.36 484,220.22 Disposal of fixed assets, intangible assets and other long-term assets

Net cash amount recovered from period 31,000.00 assets

Received from disposal of subsidiaries and other business units

net cash

Other cash received related to investing activities 10,144,833.33

Subtotal of cash inflows from investing activities 340,245,025.69 275,515,220.22 Purchase and construction of fixed assets, intangible assets and other long-term assets

7,024,469.32 5,414,710.64 Cash paid for assets

Cash paid for investment 289,000,000.00 357,000,000.00 Net increase in pledged loans

Obtain payment from subsidiaries and other business units

net cash

Cash payments related to other investment activities 84,043,277.78

Subtotal of cash outflows from investing activities 380,067,747.10 362,414,710.64 Net cash flow generated from investing activities -39,822,721.41 -86,899,490.42

3. Cash flow generated from financing activities:

Absorbing cash received from investments

Among them: subsidiaries absorb investment from minority shareholders

cash received

Cash received from borrowing 3,000,000.00

Other cash received related to financing activities 154,780.00

Subtotal of cash inflows from financing activities 3,154,780.00

Cash paid to repay debts 200,000.00

Distribution of dividends, profits or repayment of interest payments

12,750.00 56,750.00 cash

Including: Payments made by subsidiaries to minority shareholders

dividends, profits

Payment of other cash related to financing activities 188,818.00 413,209.98 Subtotal of cash outflows from financing activities 401,568.00 469,959.98 Net cash flow generated from financing activities 2,753,212.00 -469,959.98

4. The impact of exchange rate changes on cash and cash equivalents

-1,597,926.44 -48,758.59 impact

Net increase in cash and cash equivalents -2,212,427.28 -25,816,956.27

Add: Balance of cash and cash equivalents at the beginning of the period 848,808,462.70 1,013,520,736.47

Balance of cash and cash equivalents at the end of the period 846,596,035.42 987,703,780.20

(2) Adjustment of relevant items in the financial statements at the beginning of the year when the new accounting standards are first implemented starting from 2026